CDC Activates Level 1 Response for Bundibugyo Ebola in DRC and Uganda

The activation follows the outbreak's confirmation in mid-May and its expansion across health zones and displacement camps in eastern DRC. CDC incident manager Satish Pillai reported 119 total personnel deployed, including 19 newly stationed staff supporting laboratory capacity, exit screening, and data systems. Uganda closed its border with DRC while confirming domestic cases, actions that align with each state's documented interest in limiting cross-border transmission costs to their health infrastructure.

No licensed vaccine or therapeutic exists for the Bundibugyo strain, whose historical case-fatality range of 25-50 percent differs from Zaire ebolavirus. BARDA has therefore initiated platform-based vaccine development modeled on Merck's Ervebo, pre-positioned 2,500 rapid tests, and supplied experimental MBP134 monoclonal antibody doses for Oxford-led trials. These steps reflect U.S. calculations to secure domestic preparedness while managing overseas exposure risks.

The 2014-2016 West Africa epidemic triggered the same Level 1 activation after cases reached the United States. Current absence of U.S. cases linked to this outbreak does not alter the underlying transmission requirement of direct fluid contact, yet the first-month case total already exceeds prior records and strains laboratory supplies in affected zones.

DRC Ministry of Health reporting of 72 new cases and 32 deaths in a single update indicates sustained growth. Next milestones include BARDA candidate proposals due within 90 days and potential trial enrollment data from Oxford by October.